Regeneron Pharmaceuticals, Inc. REGN

788.04 (7.98) (1.00%) as of 25 Sep
Market cap
$81.3B
P/E
18.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

15.19% 14.87% 14.55% 14.04%
ROA
11.80% 11.50% 11.28% 10.83%
ROIC
9.14% 8.82% 9.20% 9.34%
Return on Tangible Assets
24.67% 24.00% 24.08% 23.56%
Average Days of Receivables
145.69 146.10 140.21 154.26
Free Cash Flow per Share
37.46 36.00 36.45 34.78
Free Cash Flow
3,881.00 3,765.20 3,791.00 3,575.20
Capital Expenditures
(1,190.00) (1,213.70) (1,221.70) (1,106.10)
Piotroski F-Score
4.00 4.00 4.00 5.00
Other line items
Cash ROIC
12.04% 11.70% 11.89% 11.23%
Accounts Receivable Turnover
2.42 2.40 2.64 2.55
Accounts Payable Turnover
2.97 2.43 2.66 2.50
Inventory Turnover
0.66 0.67 0.73 0.75
Average Days of Payables
158.49 163.15 162.59 179.90
Days of Inventory on Hand
570.67 556.14 491.29 478.62
Tax Rate
(0.11) (0.14) (0.14) (0.16)
Research and Development Expense of Revenue
39.56% 40.79% 40.66% 40.40%
Selling, General and Administrative Expense of Revenue
19.07% 18.82% 18.20% 17.65%
Share Based Compensation of Revenue
7.36% 6.93% 6.67% 6.35%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
1.11 1.11 1.13 1.08
Depreciation/Fixed assets
0.11 0.11 0.10 0.10
Capex/Depreciation
(2.27) (2.23) (2.26) (2.09)
Revenue per Share
137.53 137.12 143.46 151.12
Operating CF per Share
48.95 47.60 48.20 45.54
Capex per Share
(11.49) (11.60) (11.75) (10.76)
Capex to Sales
0.08 0.08 0.08 0.07
Net Profit Margin
32.13% 31.41% 29.65% 27.86%

Fold the line items

Columns are period end dates